Dutch rare disease specialist ProQR Therapeutics (Nasdaq: PRQR) has been given Rare Pediatric Disease (RPD) designation for its candidate QR-421a.
The US Food and Drug Administration awards the status, which provides priority review with the aim of expediting the process, to certain promising treatments for rare pediatric diseases.
ProQR is developing QR-421a for the treatment of people with retinitis pigmentosa caused by certain genetic mutations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze